Equities research analysts expect that Stealth BioTherapeutics Corp (NASDAQ:MITO) will report earnings per share of ($0.04) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Stealth BioTherapeutics’ earnings. The business is scheduled to report its next quarterly earnings report on Wednesday, November 13th.

According to Zacks, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.30) per share for the current year, with EPS estimates ranging from ($0.34) to ($0.25). For the next financial year, analysts forecast that the company will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.26) to ($0.13). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Stealth BioTherapeutics.

Stealth BioTherapeutics (NASDAQ:MITO) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04.

Several equities analysts have issued reports on the company. Cantor Fitzgerald assumed coverage on Stealth BioTherapeutics in a report on Friday, September 27th. They set an “overweight” rating and a $18.00 price objective on the stock. Nomura set a $28.00 price objective on Stealth BioTherapeutics and gave the stock a “buy” rating in a report on Friday, October 18th. HC Wainwright set a $21.00 price objective on Stealth BioTherapeutics and gave the stock a “buy” rating in a report on Friday, October 18th. Jefferies Financial Group set a $9.00 price objective on Stealth BioTherapeutics and gave the stock a “hold” rating in a report on Tuesday, October 15th. Finally, Zacks Investment Research lowered Stealth BioTherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $21.86.

MITO traded up $0.04 during trading hours on Thursday, reaching $6.47. The company’s stock had a trading volume of 2,700 shares, compared to its average volume of 21,879. The stock has a market cap of $230.15 million and a PE ratio of -4.59. The business’s 50-day moving average is $6.42 and its 200-day moving average is $10.55. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.13 and a quick ratio of 2.13. Stealth BioTherapeutics has a fifty-two week low of $4.97 and a fifty-two week high of $20.99.

Stealth BioTherapeutics Company Profile

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Further Reading: What is systematic risk?

Get a free copy of the Zacks research report on Stealth BioTherapeutics (MITO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.